1. Scrip
  2. >>Business
  3. >>Financing

IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025

New Year Still Off To Good Start With Five Offerings

 
• By Mandy Jackson

Most biopharma firms that went public in the US in 2024 had a strong start, but by year-end many were trading in negative territory and in 2025 most are below their IPO values, raising questions about IPO prospects in 2025.

Only two drug developers that went public in 2024 are still trading above their IPO values (Shutterstock)

A thriving market for initial public offerings is essential for biopharmaceutical industry growth as firms seek to expand drug development programs beyond the scope of what their venture capital backers can continue to support. And in 2024, a few more drug developers made it through the IPO window in the US than in the prior year, with 25 offerings versus 21 in 2023 – a hopeful sign for 2025.

Five biopharma firms have gone public in the US as of late February, but for IPO investors to continue to back the sector this year, drug developers that launch first-time...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By Mandy Jackson

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

More from Scrip

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.